The Relationship Between CCN3 and Rheumatoid Arthritis and Its Potential Therapeutic Value
Journal of Immunology Research · 2026-01 · 2026 (1)
DOI: 10.1155/jimr/8846865 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Immunology Research, online erschienen am 05.07.2026. Verfasst von Ye Yuan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, School of Basic Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, China, gdpu.edu.cn. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Nephroblastoma Overexpressed Protein. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Jiangxi Provincial Health Technology Key Project, Key R&D Program of Jiangxi Province, China.
Abstract (Originalsprache)
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation, progressive joint destruction, and bone damage. Despite advances in disease‐modifying antirheumatic drugs (DMARDs), unmet clinical needs arising from incomplete efficacy and safety concerns continue to drive the search for innovative therapeutic targets. Cellular communication network factor 3 (CCN3), a matricellular CCN family protein, is low in normal synovium but elevated in RA synovium and circulation, where it correlates with disease activity, anti‐cyclic citrullinated peptide (anti‐CCP) antibody titers, and IL‐6. CCN3‐associated effects may involve inflammatory‐cell recruitment, fibroblast‐like synoviocyte (FLS) activation and senescence, extracellular matrix (ECM) remodeling, cartilage degeneration, and osteoclastogenesis. Mechanistically, CCN3 may interact with RA‐relevant NF‐κB, Wnt/β‐catenin, BMP/Smad, PI3K/Akt/mTOR, IL‐6/JAK/STAT, Notch, and MAPK signaling networks. This review comprehensively examines the expression patterns, functional mechanisms, signaling pathways, and ongoing debates concerning CCN3 in RA and further explores its promise as a therapeutic target in preclinical research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, School of Basic Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, China, gdpu.edu.cn.
- Jiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial People's Hospital, Nanchang, 330006, China, jxsrmyy.cn.
- JXHC Key Laboratory of Rheumatology and Immunology, Jiangxi Provincial People's Hospital, Nanchang, 330006, China, jxsrmyy.cn.
- Department of Rheumatology and Clinical Immunology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, 330006, China, jxsrmyy.cn.
ORCID-Profile: Mengya Jiao, Lihua Duan
Förderung
- National Natural Science Foundation of China
- Jiangxi Provincial Health Technology Key Project
- Key R&D Program of Jiangxi Province, China
- Jiangxi Provincial Natural Science Foundation
- Jiangxi Province Key Laboratory of Immunology and Inflammation
Zitieren
APA
Yuan, Y., Yin, H., Jiao, M., & Duan, L. (2026). The Relationship Between CCN3 and Rheumatoid Arthritis and Its Potential Therapeutic Value. Journal of Immunology Research, 2026(1). https://doi.org/10.1155/jimr/8846865
Vancouver
Yuan Y, Yin H, Jiao M, Duan L. The Relationship Between CCN3 and Rheumatoid Arthritis and Its Potential Therapeutic Value. Journal of Immunology Research. 2026;2026(1). doi:10.1155/jimr/8846865
BibTeX
@article{Yuan2026,
author = {Yuan, Ye and Yin, Hui and Jiao, Mengya and Duan, Lihua},
title = {The Relationship Between CCN3 and Rheumatoid Arthritis and Its Potential Therapeutic Value},
journal = {Journal of Immunology Research},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/jimr/8846865}
}
EUVIMED